ACTRN12621001660875
Recruiting
未知
An Adapted Cognitive Behaviour Therapy Approach to Treat Sexuality Problems After Traumatic Brain Injury
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Traumatic brain injury
- Sponsor
- Monash University
- Enrollment
- 25
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria are as follows: (a) aged between 18 to 65 years, (b) sustained complicated mild to very severe TBI, (b) greater than three months post injury, (c) self\-reported sexuality disturbance with post injury onset.
Exclusion Criteria
- •The following exclusion criteria will be used: (a) presence of other neurological disorder, (b) history of psychotic disorder, (c) current alcohol or drug abuse, and (d) insufficient English language or cognitive capacity to provide informed consent and/or complete questionnaires or therapy tasks.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Assessment of efficacy and safety in patients with non-cancer-related pain and opioid-induced constipation.Opioid-induced constipation (OIC)Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2011-001987-24-SKAstraZeneca AB630
Active, not recruiting
Phase 1
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 20.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2017-003158-18-ESBiogen Idec Research Limited290
Active, not recruiting
Phase 1
A Controlled Study with an active treatment and a Placebo to Assess the Efficacy and Safety of Weekly Intravenous Product in Subjects with Pulmonary Emphysema due to Alpha-1 Antitrypsin DeficiencyPulmonary Emphysema due to Alpha-1-Antitrypsin DeficiencyMedDRA version: 20.0Level: LLTClassification code 10014563Term: Emphysema pulmonarySystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2013-001870-38-SEGrifols Therapeutics Inc.339
Active, not recruiting
Phase 1
A study to assess the efficacy and safety of nemolizumab (CD14152) in subjects with prurigo nodularis (PN)Prurigo NodularisMedDRA version: 20.0Level: LLTClassification code 10037084Term: Prurigo nodularisSystem Organ Class: 100000004858Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]EUCTR2019-004789-17-FRGalderma S.A.240
Recruiting
Phase 3
Chronic Migraine in Patients 12 to 17 Years of AgeHealth Condition 1: G437- Chronic migraine without auraCTRI/2021/07/034818Eli Lilly and Company India Pvt Ltd